TIME COURSE OF CHANGES IN THE SUBPOPULATION COMPOSITION OF PERIPHERAL BLOOD LYMPHOCYTES IN THE PREGRAVID PREPARATION OF WOMEN WITH RECURRENT MISCARRIAGE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Pregravid preparation that may encompass both immunocytotherapy (ICT) and medical treatments (with gestagens) occupies a special place in the therapy of idiopathic recurrent abortion. Objective. To investigate the time course of changes in the subpopulation composition of peripheral blood lymphocytes after various options of immunomodulatory therapy during pregravid preparation of women with recurrent miscarriage of alloimmune genesis. Subjects and methods. A study group consisted of 51 women with an established diagnosis of recurrent miscarriage of unclear (alloimmune) genesis. A control group comprised 15 fertile women. Pregravid preparation of the women was done by three schemes: ICT with allogeneic cells from partners, ICT together with dydrogesterone, or medical treatment with dydrogesterone. The content of the main subpopulations of immunocompetent T cells (СD3+, CD4+, CD8+), B cells (CD19+), B1 cells (CD19+CD5+), NK cells (СD56+, СD16+), as well as Treg (CD4+CD25highCD127low/-). Results. After ICT, there was a significant increase in the subpopulation of lymphocytes with the CD5+CD19+ phenotype compared to the control and no changes in the level of the other subpopulations; in the ICT + dydrogesterone group, the concentration of subpopulations with the CD56,16+, CD56+, and CD3+CD56,16+ phenotypes significantly exceeded that in the control group; and the content of Treg remained unchanged. After two dydrogesterone treatment cycles, the levels of Treg, CD200+, CD19+, CD5+19+, CD3+8+, CD3+CD56,16+ cells remained unchanged; but there was a considerable increase in the concentrations of CD3-CD8+, CD3-CD16+, CD16+, CD56+, CD3-CD56,16+, and CD56,16+ subpopulations and a substantial decrease in CD3+, CD3+CD4+ ones. Conclusion. Each of therapeutic options has a certain immunomodulatory effect, the clinical significance of which remains to be estimated in further investigations conducted during pregnancy.

Full Text

Restricted Access

About the authors

Lyubov V. Krechetova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: k_l_v_@mail.ru
Ph.D. in medical sciences, Head of Laboratory of Clinical Immunology Moscow 117997, Ac. Oparina str. 4, Russia

Valentina V. Vtorushina

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: vtorushina@inbox.ru
Ph.D. in medical sciences, doctor of laboratory diagnostics in Laboratory of Clinical Immunology Moscow 117997, Ac. Oparina str. 4, Russia

Elena L. Golubeva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: e_golubeva@oparina4.ru
Ph.D. in medical sciences, doctor of laboratory diagnostics in Laboratory of Clinical Immunology Moscow 117997, Ac. Oparina str. 4, Russia

Victoria A. Saribegova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: saribegova_v@rambler.ru
Graduate student, Department of Pregnancy Loss Prevention and Therapy Moscow 117997, Ac. Oparina str. 4, Russia

Nelly A. Khachatryan

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: nelly1986@mail.ru
Graduate student, Department of Pregnancy Loss Prevention and Therapy Moscow 117997, Ac. Oparina str. 4, Russia

Anna Aramovna Agadzanova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: aagadjanova@mail.ru
Doctor of Medicine, Department of Pregnancy Loss Prevention and Therapy Moscow 117997, Ac. Oparina str. 4, Russia

Nana K. Tetruashvili

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: n_tetruashvili@oparina4.ru
Doctor of Medicine, Head of the Department of Pregnancy Loss Prevention and Therapy Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Saraswat L., Bhattacharya S., Maheshwari A., Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. BJOG. 2010; 117(3): 245-57.
  2. van Oppenraaij R.H., Jauniaux E., Christiansen O.B., Horcajadas J.A., Farquharson R.G., Exalto N.; ESHRE Special Interest Group for Early Pregnancy (SIGEP). Predicting adverse obstetric outcome after early pregnancy events and complications: a review. Hum. Reprod. Update. 2009; 15(4): 409-21.
  3. Сидельникова В.М., Сухих Г.Т. Невынашивание беременности. Руководство для практикующих врачей. М.: МИА; 2011. 516с.
  4. Carp Howard J.A., ed. Recurrent pregnancy loss: causes, controversies and treatment. Informa UK ltd.; 2007. 290p.
  5. Chong P.J., Matzner W.L., Ching W.T. Benefit of leukocyte immunizations? Fertil. Steril. 1993; 59(1): 247-9.
  6. ChongP.J., Matzner W.L., Ching W.T. Controversy about immunotherapy. Fertil. Steril. 1993; 59(5): 1138-9.
  7. Сухих Г.Т., Ванько Л.В. Иммунология беременности. М.: Издательство РАМН; 2003. 400с.
  8. Посиссева Л.В., Малышкина А.И., Бойко Е.Л., Сотникова Н.Ю., Перетятко Л.П., Фетисова И.Н. Реабилитация репродуктивного здоровья супружеских пар с невынашиванием беременности. Иваново: «Изд-во Иваново»; 2008. 240с.
  9. Петросян Л.А. Оптимизация лимфоцитоиммунотерапии в лечении привычной потери беременности первого триместра: автореф. дисс.. канд. мед. наук. М.; 2009. 24с.
  10. Khonina N.A., Broitman E.V., Shevela E.Y., Pasman N.M., Chernykh E.R. Mixed lymphocyte reaction blocking factors (MLR-Bf) as potential biomarker for indication and efficacy of paternal lymphocyte immunization in recurrent spontaneous abortion. Arch. Gynecol. Obstet. 2013; 288(4): 933-7.
  11. Nonaka T., Takakuwa K., Ooki I., Akashi M., Yokoo T., Kikuchi A, Tanaka K. Results of immunotherapy for patients with unexplained primary recurrent abortions--prospective non-randomized cohort study. Am. J. Reprod. Immunol. 2007; 58(6): 530-6.
  12. Recurrent Miscarriage Immunotherapy Trialists Group. Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion. Am. J. Reprod Immunol. 1994; 32(3): 255.
  13. Raghupathy R., Al-Mutawa E., Al-Azemi M., Makhseed M., Azizieh F., Szekeres-Bartho J. Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J. Reprod. Immunol. 2009; 80(1-2): 91-9.
  14. Arck P., Hansen P.J., Mulac Jericevic B., Piccinni M.P., Szekeres-Bartho J. Progesterone during pregnancy: endocrine-immune cross talk in mammalian species and the role of stress. Am. J. Reprod. Immunol. 2007; 58(3): 268-79.
  15. Check J.H., Szekeres-Bartho J., O’Shaughnessy A. Progesterone induced blocking factor seen in pregnancy lymphocytes soon after implantation. Am. J. Reprod. Immunol. 1996; 35(3): 277-80.
  16. Ku C.W., Allen J.C. Jr., Malhotra R., Chong H.C., Tan N.S., 0stbye T. et al. How can we better predict the risk of spontaneous miscarriage among women experiencing threatened miscarriage? Gynecol. Endocrinol. 2015; 31(8): 647-51.
  17. Hudić I., Stray-Pedersen B., Szekeres-Bartho J., Fatusić Z., Dizdarević-Hudić L., Tomić V. et al. Maternal serum progesterone-induced blocking factor (PIBF) in the prediction of preterm birth. J. Reprod. Immunol. 2015; 109: 36-40.
  18. Szekeres-Bartho J., Weill B.J., Mike G., Houssin D., Chaouat G. Progesterone receptors in lymphocytes of liver-transplanted and transfused patients. Immunol. Lett. 1989; 22(4): 259-61.
  19. Сидельникова В.М. Подготовка и ведение беременности у женщин с привычным невынашиванием. Методические пособия и клинические рекомендации. М.: МЕДпресс-информ; 2011. 224с
  20. Chaouat G. Inflammation, NK cells and implantation: friend and foe (the good, the bad and the ugly?): replacing placental viviparity in an evolutionary perspective. J. Reprod. Immunol. 2013; 97(1): 2-13.
  21. Saito S., Shima T., Nakashima A., Shiozaki A., Ito M., Sasaki Y. What is the role of regulatory T cells in the success of implantation and early pregnancy? J. Assist. Reprod. Genet. 2007; 24(9): 379-86.
  22. Williams Zev. Inducing tolerance to pregnancy. N. Engl. J. Med. 2012; 367(12): 1159-61.
  23. Vacca P., Cantoni C., Vitale M., Prato C., Canegallo F., Fenoglio D. et al. Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc. Natl. Acad. Sci. USA. 2010; 107(26): 11918-23.
  24. Trabanelli S., Ocadlikova D., Evangelist C., Parisi S., Curti A. Induction of regulatory T Cells by dendritic cells through indoleamine 2,3-dioxygenase: a potent mechanism of acquired peripheral tolerance. Curr. Med. Chem. 2011; 18(15): 2234-9.
  25. Clark D.A., Wong K., Banwatt D., Chen Z., Liu J., Lee L. et al. CD200-dependent and nonCD200-dependent pathways of NK cell suppression by human IVIG. J. Assist. Reprod. Genet. 2008; 25(2-3): 67-72.
  26. Clark D.A. Cell surface CD200 may predict efficacy of paternal mononuclear leukocyte immunotherapy in treatment of human recurrent pregnancy loss. Am. J. Reprod. Immunol. 2009; 61: 75-84.
  27. Krechetova L.V., Nikolaeva M.A., Van’ko L.V., Ziganshina M.M., Golubeva E.L., Stepanova E.O., Sukhikh G.T. Optimal detection of serum antipaternal antileukocytic antibodies after injection of allogenic lymphocytes in woman with habitual abortions. Bulletin of Experimental Biology and Medicine. 2012; 153(5): 726-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies